Bristol-Myers Squibb: Bristol Myers Squibb's Opdivo plus Yervoy gets US FDA nod to treat adult and pediatric patients with mismatch repair deficient colorectal cancer

Bristol Myers Squibb, announced that the US Food and Drug Administration (FDA) approved Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first─line treatment of adult and pediatric patients (12